Given the uncontrolled advance of the coronavirus, which has already infected 12 million people in the United States, the National Drug Agency (FDA) authorized yesterday the use of a treatment from the Regeneron firm, used by the president, Donald Trump, when infected last October. According to the FDA, Regen-COV2, a combination of two laboratory-made antibodies, has been shown to reduce hospitalizations or ER visits for infected patients with secondary illnesses or “comorbidities.”
“Licensing these therapies can help outpatients avoid being hospitalized and ease the burden on our healthcare system,” said FDA Commissioner Stephen Hahn. His point of view is in line with that of Trump, who after recovering from the coronavirus promoted this treatment, which is more effective during the initial phase of infection, when the antibodies still have the possibility of controlling the pathogen.
In parallel, the head of the government team that leads the fight against the pandemic, Moncef Slaoui, explained yesterday that the US is scheduled to start its vaccination program against Covid-19 at the beginning of next month. FDA advisers are reportedly meeting Dec. 8-10 to discuss validation of vaccines that Pfizer and Moderna say are at least 95% effective. “Our plan is to send them to vaccination centers within 24 hours of approval,” said Slaoui, who hopes the country will achieve “herd immunity” in May.